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sions and the onset of psoriasis was about 7 months. 7 of the 
13 patients received infliximab, 3 adalimumab, and 3 certoli-
zumab pegol at onset of psoriasis. In most of the cases, anti-
TNF therapy was changed or discontinued and skin lesions 
improved.  Conclusion: Most of our described patients fea-
tured a complicated disease course of CD and had an im-
provement of the rash after changing the anti-TNF therapy. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Inflammatory bowel disease (IBD) is a chronic inflam-
matory disease of the gastrointestinal tract which in-
cludes Crohn’s disease (CD) and ulcerative colitis (UC). 
While UC is restricted to the colon and reflects a contin-
uous inflammation confined to the mucosal layer, CD is 
characterized by a discontinuous, granulomatous and 
transmural inflammation that can occur anywhere in the 
gastrointestinal tract. Environmental, genetic and immu-
nological factors as well as the intestinal microbiota have 
been considered as the major etiology of IBD. Evidence 
suggests that an epithelial barrier defect, coupled with a 
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 Abstract 
 Background and Aims: Paradoxically, psoriasis or psoriasi-
form skin lesions induced or exacerbated by anti-TNF anti-
bodies have been described. Here, we report a series of 13 
novel cases featuring exacerbation or occurrence of psoriatic 
skin lesions induced by anti-TNF antibodies in patients with 
Crohn’s disease (CD).  Methods: We performed a systematic 
analysis of exacerbation or occurrence of psoriasis or psoria-
siform skin lesions induced by anti-TNF antibodies in an in-
flammatory bowel disease patient cohort at the University 
Hospital Zurich.  Results: We identified 13 CD patients who 
developed psoriasis or psoriasiform lesions while receiving 
anti-TNF therapy. 10 of the 13 patients were female with an 
average age of 26.9 years at diagnosis. 11 of the 13 patients 
had a complicated disease. The mean time of clinical latency 
between diagnosis and onset of psoriasis was about 9.4 years, 
and the time between the beginning of all biological infu-
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dysfunctional immune response of the innate as well as 
the acquired immune system to commensal microbiota, 
resulting in either excessive up- or impaired downregula-
tion of inflammatory events, drives the development of 
chronic intestinal inflammation  [1] . The predispositions 
are genetically determined and variations in about 160 
gene loci have been associated with IBD  [2, 3] .
 Current treatment strategies include steroids, immu-
nosuppressants as well as biologicals, in particular anti-
TNF antibodies. The introduction of anti-TNFs for IBD 
was in the late 1990s and these agents have proven effi-
cacy in the induction and maintenance of remission in 
CD and more recently in UC. They are also routinely used 
in the management of rheumatologic conditions (e.g. 
rheumatoid arthritis, ankylosing spondylitis, psoriatic ar-
thritis) and psoriasis  [4] . Infliximab (IFX) was the first 
biologic agent targeting TNF and was followed by other 
anti-TNF antibodies, such as adalimumab (ADA), cer-
tolizumab pegol (CZP) and golimumab  [4–6] .
 The number of IBD patients being exposed to TNF in-
hibitors has dramatically increased in the last decade. 
Though clinical efficacy and safety of anti-TNF agents is 
well demonstrated, a significant number of patients exhibit 
side effects that often lead to discontinuation of anti-TNF 
treatment. This situation then displays a serious problem 
since further treatment options are limited and often fail.
 A certain group of complications under the treatment 
with anti-TNF antibodies that gains more and more im-
portance in the clinical management of IBD patients is 
the manifestation of psoriatic skin lesions. This phenom-
enon is seemingly paradoxical because of anti-TNF agents 
(e.g. IFX and ADA) are also effective in the treatment of 
psoriasis  [5–7] . After publication of the first case series  [8, 
9] , it nowadays appears that the magnitude of this prob-
lem has long been (and probably still is) underestimated.
 Besides the unpleasant nature of this dermopathy, 
ranging from predominant cosmetic impairment up to 
severe pruritus and psychological, sexual as well as psy-
chosocial affections, the severe impact of this side effect 
lies in the fact that a substantial number of patients need 
either to be switched to an alternative anti-TNF agent 
(with only limited efficacy) or completely be taken off 
(about 30% of patients) TNF inhibitors  [4, 9–12] , possibly 
resulting in acute IBD flares.
 Here, we describe 13 new cases of CD patients devel-
oping psoriasis or psoriasiform skin lesions while being 
under anti-TNF therapy. This adds significantly to the 
described number of somewhat over 220 such cases to 
date. A further purpose of this study was to perform a 
systematic review of reported cases with this pathology.
 Patients and Methods 
 We retrospectively identified 13 cases of anti-TNF-induced 
psoriasis or psoriasiform skin lesions in patients with CD in the 
IBD outpatient clinic at the Division of Gastroenterology and Hep-
atology, University Hospital Zurich, Switzerland, between 2007 
and 2013. A detailed review of each patient’s medical record was 
undertaken, focusing on demographics, type of IBD, years from 
diagnosis of CD, presentation, location and behavior according to 
the Vienna Classification, personal and family history of psoriasis, 
time of onset of psoriasis, site of lesions, complications, therapy, 
and outcome. In each case, the tentative diagnosis psoriasis was 
diagnosed by the gastroenterologist and in most of the cases con-
firmed by a dermatologist who carried out a biopsy of the respec-
tive skin lesions, if deemed necessary.
 Systematic Review 
 A comprehensive search was conducted using MEDLINE and 
PubMed databases from January 1946 to July 2013. The keywords 
used were: ‘Crohn’s disease’, ‘ulcerative colitis’, ‘inflammatory 
bowel disease’, ‘psoriasis’, ‘psoriatic skin lesion’, ‘anti-TNF’, ‘in-
fliximab’, ‘adalimumab’, ‘certolizumab pegol’ and ‘golimumab’,
either singly or in combination. Reports describing histological 
types of psoriasis or psoriatic skin lesions in patients who had not 
been on anti-TNF therapy at time of occurrence were excluded. 
The reference lists from the relevant articles were also searched 
manually to identify trials for possible inclusion. All available clin-
ical and pathological variables from these reports were included.
 Statistical Analysis 
 Qualitative variables were expressed as percentages with confi-
dence intervals while quantitative variables were expressed as the 
mean and standard deviation or median and interquartile range, 
according to the presence or absence of a normal distribution.
 Results 
 We identified 13 patients with the diagnosis of CD and 
a concomitant diagnosis of psoriasis or psoriasiform skin 
lesion while receiving an anti-TNF antibody (e.g. ADA, 
IFX, CZP or golimumab). Of note, no such cases in UC 
patients were found.
 Demographic Aspects 
 All patients in this case series had CD. 10 of the 13 
(77%) patients were female with the diagnosis of CD, a 
mean age of 26.9 (18–54) years at diagnosis and no per-
sonal and/or family history of psoriasis; 3 of them (23%) 
were males with a mean age of 22 (15–34) years and also 
without a history of psoriasis ( table 1 ).
 IBD Characteristics 
 Multiple other organ systems can be affected in IBD 
patients, including bones and joints, skin and eyes. In our 
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review, 8 of the 13 patients (62%) with CD had extrain-
testinal manifestations. All 8 patients were suffering from 
arthritis and 2 (25%) additionally had a manifestation of 
their skin other than psoriasis (both had an erythema no-
dosum and a pyoderma gangrenosum). In 3 patients, IBD 
was associated with arthritis and perianal inflammation 
(37.5%) or in 2 patients with arthritis in combination with 
an association of their bones (25%). 5 (38%) CD patients 
had no extraintestinal manifestation. 6 (46%) CD patients 
featured a steroid-dependent disease course and 11 of the 
13 (85%) CD patients received azathioprine at any stage 
during their disease.
 IBD Complications 
 The major intestinal IBD complications include fistu-
lae and stenosis either alone or in combination. In our 
case series, 11 of 13 patients (85%) had a complicated dis-
ease characterized either by stenosis or fistulae. Only 2 
(15%) CD patients showed an inflammatory, meaning 
non-stricturing non-penetrating disease course, and 3 
(23%) patients featured a structuring disease, while the 
majority of the 8 patients (62%) featured a penetrating 
disease. Of the 13 CD patients, 1 (8%) had inflammation 
restricted to the terminal ileum and 2 (15%) had colonic 
disease. 10 (77.0%) patients had ileocolonic disease and 2 
also had upper gastrointestinal tract involvement ( ta-
ble 2 ). In our review, 7 of 13 (54%) CD patients had un-
dergone surgery in their medical history. The mean time 
of clinical latency between the diagnosis and the first op-
eration was about 7 (1–12) years.
 Clinical Manifestations 
 For the treatment of the 13 CD patients, four different 
anti-TNF antibodies, namely IFX, ADA, CZP and golimu-
mab, were used. 11 of 13 (85%) patients had IFX, 8 (62%) 
patients ADA, and 7 (54%) patients CZP in their medical 
history. Only 1 patient was being treated with golimumab 
after receiving IFX, ADA and CZP.
 In our case series, three anti-TNF agents (IFX, ADA 
and CZP) were responsible for the induction or exacerba-
tion of psoriasis or psoriasiform lesions in CD patients. 
At the onset of skin lesions, 6 (46%) patients with CD 
were being treated exclusively with IFX, 3 with ADA 
(23%) and 3 with CZP (23%). In 1 patient, IFX as well as 
CZP were responsible for the induction or exacerbation 
of the psoriasiform lesions. The mean time of clinical la-
tency between the diagnosis and the onset of psoriasis or 
psoriasiform skin lesions was about 9.4 (1–19) years. The 
mean time of clinical latency between the beginning of all 
biological infusions and the onset of psoriasis or psoria-
siform skin lesions was averaged about 7 (3–12) months 
( table 1 ). 
 Nine of the 13 CD patients (69%) who developed pso-
riasis or psoriasiform skin lesions being treated with anti-
TNF agents saw a dermatologist and 8 (62%) received a 
skin biopsy. The skin biopsy results showed features con-
sistent with psoriasis in 3 (37.5%) patients and psoriasi-
form skin lesions in 5 (62.5%) patients.
 The most frequent sites of psoriatic or psoriasiform 
skin lesions were the limbs (54%) in 7 patients, followed 
by the scalp (31%) in 4, and the trunk (23%) in 3 patients. 
Most had more than one site of skin lesions ( fig. 1 ).
 Table 2.  Vienna Classification in 13 CD patients
A1  A2
B1 B2 B3  B1 B2 B3
L1 1 (8%)
L2 1 (8%) 1 (8%)
L3 2 (15%) 6 (45%)
L3/4 1 (8%) 1 (8%)
 Vienna Classification: A (age at diagnosis): A1 <40 years, A2 
>40 years; L (location): L1 terminal ileum, L2 colon, L3 ileocolon, 
L4 upper GI; B (behavior): B1 non-stricturing, non-penetrating, 
B2 stricturing, B3 penetrating.
 Table 1.  Summary of data of 13 CD patients with psoriatic lesions 
induced or exacerbated by anti-TNF agents
Gender
Female 10 (77)
Male 3 (23)
Age at diagnosis, years 26.9 (18 – 54)
New onset of skin lesion 13 (100)
Previous history of psoriasis
No (de novo or induced psoriasis) 13 (100)
Yes (exacerbated preexisting psoriasis) –
Anti-TNF treatment used at the time of skin lesion
IFX 7 (54)
ADA 3 (23)
CZP 3 (23)
Time from diagnosis to onset of rash, years 9.4 (1 – 19)
Time from start of anti-TNF to onset of rash, months 7 (3 – 12)
IFX 8.7 (2 – 12)
ADA 6 (3 – 9)
CZP 4 (4 – 4)
Values represent n (%) or median (range).
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 Management 
 In 4 of 13 (31%) CD patients, the current anti-TNF 
treatment was stopped and switched to a different med-
ication (e.g. methotrexate, steroids or azathioprine). All 
had a topical treatment and in 3 cases an improvement 
of their skin lesions was observed. In 4 (31%) patients 
the current anti-TNF agents were switched to another 
one. All of them also featured an improvement. One
patient (8%) was switched first to another anti-TNF 
agent, but as the dermatopathy recurred, the patient was 
switched to an experimental drug (interleukin-6 anti-
body) and anti-TNF treatment was stopped. In 2 (15%) 
patients the medication with anti-TNF agents was con-
tinued and not suspended; they had an improvement of 
their skin lesions under topical treatment with cortico-
steroids. In another 2 patients (15%) the final decision 
about how to continue with anti-TNF therapy was not 
decided. Topical treatment was the anti-psoriatic thera-
py most often used (85%), with a topical corticosteroid 
resulting in improvement of skin lesions in nearly in all 
cases.
 Discussion 
 Since their introduction in the late 1990s, anti-TNF 
agents have acquired a prominent place in the treatment 
of IBD and psoriasis  [4] . Paradoxically, numerous reports 
of new onset or exacerbation of psoriasis under treatment 
with anti-TNF agents have been observed in patients with 
IBD. Although the first case of anti-TNF agent (IFX)-in-
duced psoriatic lesions was described in a patient with CD 
 [13] , most of the skin lesions concerned were obtained 
from the rheumatologic literature  [14] . An increasing 
number of IBD patients developed a psoriatic skin lesion 
as described in numerous reviews  [15–17] and the latest 
overview in patients with IBD mentions more than 220 
cases  [18] .
 In our case series representing 13 new cases, we found 
that all of the patients with anti-TNF agent-induced pso-
riasis or psoriasiform skin lesions were patients with CD 
without a personal history of psoriasis. This observation 
is in good accordance with previous data in the literature 
where CD patients are also described to be mainly affect-
a b c
d e
 Fig. 1. Examples of TNF-induced psoria-
sis lesions: limbs ( a ), palmoplantar ( b ,  c ), 
trunk ( d ), and manifestation of the skin – 
pyoderma gangrenosum ( e ). 
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ed. However, to our surprise, we did not find any UC pa-
tients featuring such a pathology in our outpatient clinic 
 [16, 18, 19] . In our experience, CD patients developing 
psoriasis or psoriasiform skin lesions were mainly female 
with CD (77%), while in the literature the male:female 
ratio seems to be mainly equivalent.
 In the literature it is recommended that patients devel-
oping psoriasis or psoriasiform skin lesions while receiv-
ing anti-TNF therapy should be evaluated by a derma-
tologist  [20, 21] . In our case series, 9 patients (69%) saw 
a dermatologist and 8 (62%) had a skin biopsy. Their his-
topathological assessments revealed the diagnosis of a 
psoriasiform lesion in 5 (62.5%) patients as the most re-
ported form of skin lesion and the diagnosis of psoriasis 
in the biopsy of 3 (37.5%) patients. In the other cases the 
skin lesions were described as a psoriasiform lesion. Be-
cause there is no exact and clear definition of psoriasi-
form or psoriasis-like lesions, many of these cutaneous 
reactions may actually be the classic type of psoriasis. 
However, to classify and diagnose the respective skin le-
sions accurately and to initiate adequate treatment, it 
might be the best option that patients who developed pso-
riasis or psoriasiform skin lesions while undergoing anti-
TNF therapy should be evaluated by a dermatologist  [20, 
21] .
 Our observed sites of psoriasis or psoriasiform skin le-
sions by patients with CD were the limbs in 7 patients 
(54%), followed by the scalp (31%) in 4, and the trunk 
(23%) in 3 patients. This is also in accordance with other 
reviews  [16, 19] .
 Multiple other organ systems can be affected in IBD 
patients, including bones and joints, skin and eyes  [22, 
23] . In our case series, 8 of 13 (62%) patients had extrain-
testinal manifestations; all had IBD-associated arthritis/
arthropathy. Two patients (25%) also had a manifestation 
of their skin (both had an erythema nodosum and a pyo-
derma gangrenosum) and 2 patients a manifestation of 
their bones (25%). This is also well in line with previous 
findings  [24, 25] .
 The multitude of perianal complications in CD pa-
tients includes fissures, fistulae, abscesses, and stenosis, 
either alone or in combination. In our case series, 85% 
patients had a complicated disease characterized either by 
stenosis or fistulae. The medical therapy is considered to 
be the treatment modality of choice for most IBD patients 
while operative management is reserved for individuals 
who fail medical treatment or develop potentially life-
threatening complications. However, most patients with 
IBD ultimately require one or more operations over their 
lifetime. In our review, 7 of 13 (54%) CD patients had un-
dergone surgery in their medical history with a mean time 
of clinical latency between the diagnosis and the first op-
eration of 7 (1–12) years. Previous studies have shown 
similar results  [26–31] .
 In our case series, 13 patients with CD had been treat-
ed with four different anti-TNF agents, IFX, ADA, CZP 
or golimumab, and three of them (except golimumab) 
were responsible for the induction or exacerbation of 
psoriasis or psoriasiform lesions in our case. Most of the 
patients (54%) received IFX. This observation is in good 
accordance with other literature  [16, 18, 19] . The major-
ity of the IFX therapy likely reflects the fact that it was the 
first biological agent available on the market and because 
of that the drug has been used longer than the other anti-
TNF agents.
 The duration of anti-TNF therapy prior to the onset of 
the rash is highly variable suggesting that an environmen-
tal trigger may also be involved  [16, 18] . The mean time 
of clinical latency between the diagnosis and the onset of 
all biological infusions was about 9.4 (1–19) years and the 
mean time between the beginning of the biological ther-
apy and the onset of psoriasis or psoriasiform skin lesions 
in our case series was about 7 (3–12) months.
 At this time, no guideline exists for treating psoriasis 
or psoriasiform skin lesions in patients with IBD under 
treatment with anti-TNF agents. There is a wide range of 
therapeutic approaches, but there is a disagreement 
whether discontinuation of the biological is needed to 
achieve an improvement or complete resolution of the le-
sions  [16, 18] .
 In our patient collective, anti-TNF treatment was ei-
ther stopped and the patient was switched to a different, 
non-anti-TNF medication (e.g. methotrexate, steroids or 
azathioprine), anti-TNF agents were switched to another 
one, or the anti-TNF agents were continued and not sus-
pended. Of note, all three approaches were successful, at 
least in some of the patients and/or in combination with 
specific psoriasis treatment. Topical steroids are the treat-
ment of choice for skin lesions alone or in combination 
with other topical drugs or phototherapy. In our case se-
ries, 85% had a topical treatment, mostly with topical ste-
roids and most of our patients showed an improvement 
of skin lesions.
 Although psoriatic lesions that are induced or exacer-
bated by anti-TNF agents in patients with IBD have been 
reported, their immunopathogenetic mechanism has not 
yet been elucidated  [15, 18] . It is known that T cells play 
a key role for the development of chronic inflammatory 
conditions such as IBD, psoriasis, rheumatoid arthritis or 
systemic lupus erythematosus.
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 Due to the surprising nature of this induced dermopa-
thy, as anti-TNF agents are also largely and successfully 
used in the treatment of psoriasis, the term paradoxical 
psoriasis has been coined. To date, the pathogenesis of 
such psoriatic lesions occurring under anti-TNF therapy 
still largely remains obscure. All in all, the direct mecha-
nism of action of these agents, namely neutralization of 
TNF, most likely is a key element in the pathogenesis. A 
dysbalance between TNF and interferon-α seems to be of 
great importance  [32] . Interferon-α is produced in der-
mal plasmacytoid dendritic cells, is negatively regulated 
by TNF  [33] and is known as a key driving factor in the 
pathogenesis of psoriatic skin lesion development  [34, 
35] . However, other cytokine and T-cell pathways were 
also identified as potential key players and this was main-
ly driven by the recognized overlap of candidate genes in 
IBD on the one hand and psoriasis as well as eczema on 
the other  [36, 37] . Nevertheless, the rising number of IBD 
patients developing psoriatic skin lesions under anti-TNF 
therapy makes the need for further investigation about 
the pathogenetic mechanisms of these complications ob-
vious. A better pathogenetic understanding would clearly 
help to define and improve treatment strategies for this 
complication.
 All in all, we show that psoriatic skin lesions in CD pa-
tients under anti-TNF therapy occur mainly in females 
featuring a complicated disease course. Since these pa-
tients are obviously difficult to treat anyway, the onset of 
psoriatic skin lesions makes their treatment even more 
difficult. Therefore, our study might contribute to better 
characterization of such patients.
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